Key Points
- Director Laura Brege sold 14,167 shares at an average of $94.21, worth about $1.33 million, reducing her stake by 47.43% to 15,703 shares.
- Mirum reported quarterly revenue of $185.72 million, up 39.6% year over year and above estimates, but its loss of $0.87 per share was wider than analysts’ expected $0.49 loss.
- Analysts’ consensus rating is Moderate Buy, with an average price target of $155.56; shares recently traded at $93.99.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) Director Laura Brege sold 14,167 shares of the business's stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $94.21, for a total transaction of $1,334,673.07. Following the completion of the sale, the director owned 15,703 shares of the company's stock, valued at approximately $1,479,379.63. The trade was a 47.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Mirum Pharmaceuticals Trading Up 0.7%
Shares of Mirum Pharmaceuticals stock traded up $0.66 during trading on Friday, reaching $93.99. The company's stock had a trading volume of 331,049 shares, compared to its average volume of 616,358. The company has a quick ratio of 1.98, a current ratio of 2.07 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 52-week low of $63.23 and a 52-week high of $130.00. The firm's 50-day moving average is $88.79 and its two-hundred day moving average is $98.41. The company has a market cap of $6.14 billion, a price-to-earnings ratio of -6.08 and a beta of 0.75.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.38). The business had revenue of $185.72 million during the quarter, compared to analysts' expectations of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. Mirum Pharmaceuticals's revenue for the quarter was up 39.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.05 EPS. On average, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.47 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC boosted its position in Mirum Pharmaceuticals by 87.8% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 20,123 shares of the company's stock valued at $1,720,000 after buying an additional 9,409 shares during the period. HighVista Strategies LLC grew its holdings in Mirum Pharmaceuticals by 79.0% in the 3rd quarter. HighVista Strategies LLC now owns 26,660 shares of the company's stock worth $2,279,000 after acquiring an additional 11,768 shares during the last quarter. Bleakley Financial Group LLC bought a new stake in Mirum Pharmaceuticals in the 3rd quarter worth $1,128,000. Impax Asset Management Group plc purchased a new position in shares of Mirum Pharmaceuticals in the third quarter valued at about $8,548,000. Finally, Ground Swell Capital LLC purchased a new position in shares of Mirum Pharmaceuticals in the third quarter valued at about $564,000.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the stock. Weiss Ratings lowered shares of Mirum Pharmaceuticals from a "sell (d)" rating to a "sell (d-)" rating in a research report on Thursday, October 22nd. Wall Street Zen downgraded Mirum Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, September 6th. Leerink Partners lowered their target price on Mirum Pharmaceuticals from $154.00 to $140.00 and set an "outperform" rating for the company in a research note on Thursday, November 5th. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an "outperform" rating in a report on Tuesday, September 29th. Finally, Evercore restated an "outperform" rating and set a $146.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $155.56.
Get Our Latest Stock Analysis on MIRM
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
